https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf

Кратко: 80 пациентов в стационаре принимали комбинацию гидроксихлорохина и азитромицина, в течение 5–8 дней почти все выздоровели.

Abstract
We need an effective treatment to cure COVID–19 patients and to decrease the virus carriage duration. In 80 in–patients receiving a combination of hydroxychloroquine and azithromycin we noted a clinical improvement in all but one 86 year–old patient who died, and one 74 year–old patient still in intensive care unit. A rapid fall of nasopharyngeal viral load tested by qPCR was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% patients at Day5. This allowed patients to rapidly be discharge from highly contagious wards with a mean length of stay of five days. We believe other teams should urgently evaluate this cost–effective therapeutic strategy, to both avoid the spread of the disease and treat patients as soon as possible before severe respiratory irreversible complications take hold.

Индийский совет медицинских исследований (ICMR) одобрил использование гидроксихлорохина в качестве профилактического препарата для коронавируса

[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]
[Therapeutic Application of Chloroquine in Clinical Trials for COVID–19]
[Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID–19: a secondary analysis of an open label non–randomized clinical trial (Gautret et al, 2020)]

Написал logixor на stopcovid.d3.ru / комментировать

Взято отсюда